Prescient Therapeutics, Ltd.   Report issue

For profit Phase 1 Phase 2
Founded: Melbourne Australia (1987)

Organization Overview

First Clinical Trial
2002
NCT00332930
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Alternative names

Prescient Therapeutics, Ltd. | Virax Pty. Ltd,

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Disease (Phase 2)

Carcinoma, Ovarian Epithelial (Phase 2)

Leukemia (Phase 2)

Neoplasm Metastasis (Phase 1)

Neoplasms (Phase 1)

Ovarian Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 8